메뉴 건너뛰기




Volumn 12, Issue 1, 2014, Pages 152-155

Should we lower lipids in nonalcoholic fatty liver disease?

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TRIACYLGLYCEROL; HYPOCHOLESTEROLEMIC AGENT;

EID: 84890216105     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.07.041     Document Type: Review
Times cited : (10)

References (29)
  • 1
    • 77950233673 scopus 로고    scopus 로고
    • A fresh look at NASH pathogenesis. Part 1: the metabolic movers
    • Larter C.Z., Chitturi S., Farrell G.C. A fresh look at NASH pathogenesis. Part 1: the metabolic movers. J Gastroenterol Hepatol 2010, 25:672-690.
    • (2010) J Gastroenterol Hepatol , vol.25 , pp. 672-690
    • Larter, C.Z.1    Chitturi, S.2    Farrell, G.C.3
  • 2
    • 84859404868 scopus 로고    scopus 로고
    • Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications
    • Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology 2012, 142:711-725.
    • (2012) Gastroenterology , vol.142 , pp. 711-725
    • Cusi, K.1
  • 3
    • 84877585029 scopus 로고    scopus 로고
    • NAFLD in Asia-as common and important as in the West
    • Farrell G.C., Wong V.W., Chitturi S. NAFLD in Asia-as common and important as in the West. Nat Rev Gastro Hep 2013, 10:307-318.
    • (2013) Nat Rev Gastro Hep , vol.10 , pp. 307-318
    • Farrell, G.C.1    Wong, V.W.2    Chitturi, S.3
  • 4
    • 84865545850 scopus 로고    scopus 로고
    • Association between diabetes, family history of diabetes and risk of non-alcoholic steatohepatitis and fibrosis
    • Loomba R., Abraham M., Unalp A., et al. Association between diabetes, family history of diabetes and risk of non-alcoholic steatohepatitis and fibrosis. Hepatology 2012, 56:943-951.
    • (2012) Hepatology , vol.56 , pp. 943-951
    • Loomba, R.1    Abraham, M.2    Unalp, A.3
  • 5
    • 84861332191 scopus 로고    scopus 로고
    • Non-high-density lipoprotein cholesterol as a biomarker for non-alcoholic steatohepatitis
    • Corey K.E., Lai M., Gelrud L.G., et al. Non-high-density lipoprotein cholesterol as a biomarker for non-alcoholic steatohepatitis. Clin Gastroenterol Hepatol 2012, 10:651-656.
    • (2012) Clin Gastroenterol Hepatol , vol.10 , pp. 651-656
    • Corey, K.E.1    Lai, M.2    Gelrud, L.G.3
  • 6
    • 22344452893 scopus 로고    scopus 로고
    • The natural history of nonalcoholic fatty liver disease: a population-based cohort study
    • Adams L.A., Lymp J.F., St Sauver J., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005, 129:113-121.
    • (2005) Gastroenterology , vol.129 , pp. 113-121
    • Adams, L.A.1    Lymp, J.F.2    St Sauver, J.3
  • 7
    • 84862517200 scopus 로고    scopus 로고
    • Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD)
    • Musso G., Cassader M., Rosina F., et al. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD). Diabetologia 2012, 55:885-904.
    • (2012) Diabetologia , vol.55 , pp. 885-904
    • Musso, G.1    Cassader, M.2    Rosina, F.3
  • 8
    • 78649890465 scopus 로고    scopus 로고
    • Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Artorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis
    • Athyros V.G., Tziomalos K., Gossios T.D., et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Artorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010, 376:1916-1922.
    • (2010) Lancet , vol.376 , pp. 1916-1922
    • Athyros, V.G.1    Tziomalos, K.2    Gossios, T.D.3
  • 9
    • 33645888317 scopus 로고    scopus 로고
    • National Lipid Association Statin Safety Task Force Liver Expert Panel. An assessment of statin safety by hepatologists
    • Cohen D.E., Anania F.A., Chalasani N. National Lipid Association Statin Safety Task Force Liver Expert Panel. An assessment of statin safety by hepatologists. Am J Cardiol 2006, 97:77C-81C.
    • (2006) Am J Cardiol , vol.97
    • Cohen, D.E.1    Anania, F.A.2    Chalasani, N.3
  • 10
    • 77955690182 scopus 로고    scopus 로고
    • Hepatic lipotoxicity and pathogenesis of nonalcoholic steato-hepatitis: the central role of nontriglyceride fatty acid metabolites
    • Neuschwander-Tetri B.A. Hepatic lipotoxicity and pathogenesis of nonalcoholic steato-hepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010, 52:774-788.
    • (2010) Hepatology , vol.52 , pp. 774-788
    • Neuschwander-Tetri, B.A.1
  • 11
    • 56649094325 scopus 로고    scopus 로고
    • Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease
    • Malhi H., Gores G. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis 2008, 28:360-369.
    • (2008) Semin Liver Dis , vol.28 , pp. 360-369
    • Malhi, H.1    Gores, G.2
  • 12
    • 36349024819 scopus 로고    scopus 로고
    • A lipidomic analysis of nonalcoholic fatty liver disease
    • Puri P., Baillie R.A., Wiest M.M., et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007, 46:1081-1090.
    • (2007) Hepatology , vol.46 , pp. 1081-1090
    • Puri, P.1    Baillie, R.A.2    Wiest, M.M.3
  • 13
    • 61849095626 scopus 로고    scopus 로고
    • Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH
    • Caballero F., Fernández A., De Lacy A.M., et al. Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. JHepatol 2009, 50:789-796.
    • (2009) JHepatol , vol.50 , pp. 789-796
    • Caballero, F.1    Fernández, A.2    De Lacy, A.M.3
  • 14
    • 49649110937 scopus 로고    scopus 로고
    • Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis
    • Wouters K., van Gorp P.J., Bieghs V., et al. Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology 2008, 48:474-486.
    • (2008) Hepatology , vol.48 , pp. 474-486
    • Wouters, K.1    van Gorp, P.J.2    Bieghs, V.3
  • 16
    • 84861563506 scopus 로고    scopus 로고
    • Beyond reasonable doubt: who is the culprit in lipotoxicity in NAFLD/NASH?
    • Arteel G.E. Beyond reasonable doubt: who is the culprit in lipotoxicity in NAFLD/NASH?. Hepatology 2012, 55:2030-2032.
    • (2012) Hepatology , vol.55 , pp. 2030-2032
    • Arteel, G.E.1
  • 17
    • 80053612479 scopus 로고    scopus 로고
    • Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis
    • Van Rooyen D.M., Larter C.Z., Haigh W.G., et al. Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. Gastroenterology 2011, 141:1393-1403.
    • (2011) Gastroenterology , vol.141 , pp. 1393-1403
    • Van Rooyen, D.M.1    Larter, C.Z.2    Haigh, W.G.3
  • 18
    • 84860469242 scopus 로고    scopus 로고
    • Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease
    • Min H.K., Kapoor A., Fuchs M., et al. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab 2012, 15:665-674.
    • (2012) Cell Metab , vol.15 , pp. 665-674
    • Min, H.K.1    Kapoor, A.2    Fuchs, M.3
  • 19
    • 84879132692 scopus 로고    scopus 로고
    • Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice
    • Van Rooyen D.M., Gan L.T., Yeh M.M., et al. Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice. J Hepatol 2013, 59:144-152.
    • (2013) J Hepatol , vol.59 , pp. 144-152
    • Van Rooyen, D.M.1    Gan, L.T.2    Yeh, M.M.3
  • 20
    • 36348935003 scopus 로고    scopus 로고
    • Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet
    • Matsuzawa N., Takamura T., Kurita S., et al. Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology 2007, 46:1392-1403.
    • (2007) Hepatology , vol.46 , pp. 1392-1403
    • Matsuzawa, N.1    Takamura, T.2    Kurita, S.3
  • 21
    • 77954601497 scopus 로고    scopus 로고
    • A human-type non-alcoholic steatohepatitis model with advanced fibrosis in rabbits
    • Ogawa T., Fujii H., Yoshizato K., et al. A human-type non-alcoholic steatohepatitis model with advanced fibrosis in rabbits. Am J Pathol 2010, 177:153-165.
    • (2010) Am J Pathol , vol.177 , pp. 153-165
    • Ogawa, T.1    Fujii, H.2    Yoshizato, K.3
  • 22
    • 80055026523 scopus 로고    scopus 로고
    • Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition
    • Charlton M., Krishnan A., Viker K., et al. Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol 2011, 301:G825-G834.
    • (2011) Am J Physiol Gastrointest Liver Physiol , vol.301
    • Charlton, M.1    Krishnan, A.2    Viker, K.3
  • 23
    • 84866736015 scopus 로고    scopus 로고
    • Dietary trans-fatty acid induced NASH is normalized following loss of trans-fatty acids from hepatic lipid pools
    • Neuschwander-Tetri B.A., Ford D.A., Acharya S., et al. Dietary trans-fatty acid induced NASH is normalized following loss of trans-fatty acids from hepatic lipid pools. Lipids 2012, 47:941-950.
    • (2012) Lipids , vol.47 , pp. 941-950
    • Neuschwander-Tetri, B.A.1    Ford, D.A.2    Acharya, S.3
  • 24
    • 77956634470 scopus 로고    scopus 로고
    • High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma co-enzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis
    • Kohli R., Kirby M., Xanthakos S.A., et al. High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma co-enzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology 2010, 52:934-944.
    • (2010) Hepatology , vol.52 , pp. 934-944
    • Kohli, R.1    Kirby, M.2    Xanthakos, S.A.3
  • 25
    • 33845872811 scopus 로고    scopus 로고
    • In vivo responsiveness to ezetimibe correlates with Niemann-Pick C1-like-1 (NPC1L1) binding affinity: comparison of multiple species NPC1L1 orthologs
    • Hawas B.E., O'Neill K.A., Yao X., et al. In vivo responsiveness to ezetimibe correlates with Niemann-Pick C1-like-1 (NPC1L1) binding affinity: comparison of multiple species NPC1L1 orthologs. Mol Pharm 2007, 71:19-29.
    • (2007) Mol Pharm , vol.71 , pp. 19-29
    • Hawas, B.E.1    O'Neill, K.A.2    Yao, X.3
  • 26
    • 84886142392 scopus 로고    scopus 로고
    • Lipid modifiers and NASH: statins, ezetimibe, fibrates, and other agents
    • Wiley-Blackwell, Oxford, G.C. Farrell, A.J. McCullough, C.P. Day (Eds.)
    • Musso G., Molinaro F., Paschetta E., et al. Lipid modifiers and NASH: statins, ezetimibe, fibrates, and other agents. Non-alcoholic fatty liver disease: a practical guide 2013, 293-307. Wiley-Blackwell, Oxford. G.C. Farrell, A.J. McCullough, C.P. Day (Eds.).
    • (2013) Non-alcoholic fatty liver disease: a practical guide , pp. 293-307
    • Musso, G.1    Molinaro, F.2    Paschetta, E.3
  • 27
    • 33750606061 scopus 로고    scopus 로고
    • Long-term follow-up of patients with NAFLD and elevated liver enzymes
    • Ekstedt M., Franzen L.E., Mathiesen U.L., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44:865-873.
    • (2006) Hepatology , vol.44 , pp. 865-873
    • Ekstedt, M.1    Franzen, L.E.2    Mathiesen, U.L.3
  • 28
    • 78651473467 scopus 로고    scopus 로고
    • Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease
    • Park H., Shima T., Yamaguchi K., et al. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol 2011, 46:101-107.
    • (2011) J Gastroenterol , vol.46 , pp. 101-107
    • Park, H.1    Shima, T.2    Yamaguchi, K.3
  • 29
    • 84880664792 scopus 로고    scopus 로고
    • Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and non-alcoholic fatty liver disease
    • Mudaliar S., Henry R.R., Sanyal A.J., et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and non-alcoholic fatty liver disease. Gastroenterology 2013, 145:574-582.
    • (2013) Gastroenterology , vol.145 , pp. 574-582
    • Mudaliar, S.1    Henry, R.R.2    Sanyal, A.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.